NOVARTIS N
Novartis AG develops, manufactures, and markets healthcare products internationally. It offers prescription medicines for patients and physicians. Focus areas include cardiovascular, renal, immunology, neuroscience, oncology, ophthalmology, and hematology. Novartis has partnerships with Alnylam Pharmaceuticals and Dawn Health to develop and commercialize therapies.
Overview
Strengths
- With an appreciation Potential of 33.13%, based on our fundamental analysis, it suggests the stock may be undervalued.
- Current Price to Earnings Ratio (18.73) is lower than the sector mean (81.73).
- The company has low debt. Net Debt to EBITDA Ratio is 0.86 and it is lower than the sector mean.
- The company has high returns. ROIC (23.97%) is higher than the sector mean (16.32%).
- EV/EBIT (16.50) is lower than the sector mean.
- Price to free cash flow (16.20) is lower than the sector mean.
- Strong EBITDA Margin of 41.53%.
Weaknesses
- No significant weaknesses identified based on the analyzed metrics.
Key Financial Data
| Indicator | Value |
|---|
| PER | 18.7 |
| EV/EBITDA | 11.6 |
| Price/Free Cash Flow' | 16.2 |
| ROIC | 24.0% |
| Net Debt/EBITDA | 0.9 |